Article info

Download PDFPDF

Original research
Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study

Authors

  1. Correspondence to Professor Maya H Buch; maya.buch{at}manchester.ac.uk
View Full Text

Citation

Buch MH, Bhatt DL, Charles-Schoeman C, et al
Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study

Publication history

  • Received November 15, 2023
  • Accepted March 24, 2024
  • First published April 12, 2024.
Online issue publication 
April 12, 2024
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.